Catalogo Ricerca

Catalogo Ricerca: [57838] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 47394
- 1.1 Articolo in rivista 39788
- 1.1.1 Articolo in rivista - Review 1694
- 1.1.2. Articolo in Rivista - Letter 919
- 1.1.3. Articolo in Rivista - Comment, Editorial, Note, Reply 1175
- 1.1.4. Guidelines, Consensus 112
- 1.1.5. Erratum 204
- 1.2 Recensione in rivista 285
- 1.3 Scheda bibliografica 14
- 1.4 Nota a sentenza 0
- 1.5 Abstract in rivista 3191
- 1.6 Traduzione in rivista 12

2 Contributo in Volume 3205

3 Libro 783
- 3.1 Monografia o trattato scientifico 646
- 3.2 Concordanza 0
- 3.3 Indice 5
- 3.4 Bibliografia 12
- 3.5 Edizione critica 25
- 3.6 Pubblicazione di fonti inedite 5
- 3.7 Commento scientifico 13
- 3.8 Traduzione di libro 77

4 Contributo in Atti di Convegno (Proceeding) 5713
- 4.1 Contributo in Atti di convegno 2273
- 4.2 Abstract in Atti di convegno 3025
- 4.3 Poster 415

5 Altro 113
- 5.01 Preprint 13
- 5.02 Composizione 0
- 5.03 Disegno 0
- 5.04 Design 0
- 5.05 Performance 3
- 5.06 Esposizione 0
- 5.07 Mostra 1
- 5.08 Manufatto 1
- 5.09 Prototipo d'arte e relativi progetti 0
- 5.10 Cartografia 0
- 5.11 Banca dati 1
- 5.12 Software 12
- 5.13 Altro 82
- 5.14 Progetto architettonico 0
- 5.15 Articolo su portale o periodico 0

6 Brevetti 176
- 6.1 Brevetto 176

7 Curatele 199
- 7.1 Curatela 199

8 Tesi di dottorato 255
- 8.1 Tesi di dottorato 255

Prodotti recenti

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine

Unlabelled: Copyright: © 2026 Crane et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Purpose: The discovery of KRAS G12C as a therapeutic target has transformed oncology with the development of specific inhibitors. This study aimed to characterize the prevalence and clinicogenomic features ...

Integrating China's Oncology Innovations into the Global Landscape: A Strategic Blueprint for Precision, Partnership, and Purpose

: Global clinical oncology research is experiencing a profound structural shift, evolving from a historical underrepresentation of minority groups in Western-centric trials to a new representational imbalance marked by an increasing reliance on Chinese patient populations due to the nation's accelerating drug research and development. This article dissects this changing dynamic and proposes a systematic framework for a next-generation global oncology research and development paradigm that is ...

Distribution and age-interactions of cortical thickness associated with specific classes of medication used to treat obsessive-compulsive disorder: Results from the international ENIGMA consortium

: MRI studies have revealed structural brain abnormalities in obsessive-compulsive disorder (OCD). Less is known about how age and medication influence them. We analyzed cortical thickness (CT) data from the ENIGMA-OCD Consortium, the world's largest OCD MRI database (46 datasets from 35 centers). Subjects comprised 2057 healthy controls, 1167 unmedicated individuals with OCD, and 1073 individuals with OCD taking one or more psychiatric medications at time of scan. Using a harmonized FreeSurf...

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center

Purpose: to reassess the prognostic value of positive surgical margins (PSM) after partial nephrectomy (PN) in terms of relapse-free survival (RFS), progression-free survival (PFS), overall survival (OS) and cancer-specific mortality (CSM) within a large cohort spanning changing surgical eras, including the progressive adoption of minimally invasive approaches. Materials and methods: We retrospectively analyzed 1441 patients who underwent PN for cM0 renal tumors between 2000 and 2024 at a ter...

Bladder Preservation After Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality

: Bladder preservation after neoadjuvant therapy for muscle-invasive bladder cancer remains investigational. While randomized validation is awaited, growing prospective data, consensus standardization, and biomarker-driven strategies are transforming bladder-sparing strategies from an empirical alternative into a disciplined, evidence-maturing paradigm towards bladder-intact cure.

Scopri

Accesso al fulltext

no fulltext48855
open4983
reserved3845
partially open115
embargoed39
mixed1